Revolve Wealth Partners LLC Trims Stake in Johnson & Johnson (NYSE:JNJ)

Revolve Wealth Partners LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,476 shares of the company’s stock after selling 1,964 shares during the quarter. Revolve Wealth Partners LLC’s holdings in Johnson & Johnson were worth $1,226,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Quarry LP purchased a new position in Johnson & Johnson during the second quarter valued at $49,000. Ashburton Jersey Ltd bought a new position in shares of Johnson & Johnson in the 2nd quarter worth about $8,771,000. Mattson Financial Services LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $3,407,000. First Financial Bank Trust Division grew its holdings in Johnson & Johnson by 1.3% in the third quarter. First Financial Bank Trust Division now owns 62,803 shares of the company’s stock worth $10,178,000 after purchasing an additional 779 shares during the period. Finally, Davis Capital Management increased its stake in shares of Johnson & Johnson by 4.4% during the third quarter. Davis Capital Management now owns 10,432 shares of the company’s stock valued at $1,691,000 after purchasing an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on JNJ. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Guggenheim raised their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Leerink Partners dropped their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Finally, Raymond James dropped their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $170.44.

Insider Buying and Selling

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ opened at $152.78 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company’s 50 day moving average is $147.73 and its 200 day moving average is $156.10.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.